FINASTERIDE
15 Limited Use · 8 not a benefit
Other products in the same Health Canada class (D11A, G04C, G04CB) — coverage varies; not interchangeable
- Dutasteride (Avodart): limited Use 384, 385
- Tamsulosin (Flomax CR Tab): general benefit, Not a benefit
- Alfuzosin (Xatral): limited Use 351, 352
- Silodosin (Rapaflo): limited Use 351, 352, Not a benefit
- Tacrolimus (Prograf): limited Use 173, Limited Use 383, Limited Use 410
Auro-Finasteride · DIN 02405814 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Finasteride · DIN 02405814
Manufacturer: Auro Pharma Inc.; listing date 2013-07-30
Health Canada: Marketed since 2013-05-30 · brand AURO-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Auro pharma inc · schedule Prescription
Auro-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89058 · Verify on the e-Formulary ↗ (DIN 02405814)
Source record
DIN 02405814: Auro-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405814
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89058
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405814
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Finasteride · DIN 02445077 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Finasteride · DIN 02445077
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2015-10-14 · brand FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Sanis health inc · schedule Prescription
Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93028 · Verify on the e-Formulary ↗ (DIN 02445077)
Source record
DIN 02445077: Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445077
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93028
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2025-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445077
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Finasteride · DIN 02447541 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Finasteride · DIN 02447541
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2015-11-25 · brand FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93313 · Verify on the e-Formulary ↗ (DIN 02447541)
Source record
DIN 02447541: Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447541
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93313
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2020-03-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447541
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Finasteride Tablets USP · DIN 02355043 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Finasteride Tablets USP · DIN 02355043
Manufacturer: Accord Healthcare Inc.; listing date 2010-12-14
Health Canada: Marketed since 2014-11-13 · brand ACH-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Accord healthcare inc · schedule Prescription
Finasteride Tablets USP: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84031 · Verify on the e-Formulary ↗ (DIN 02355043)
Source record
DIN 02355043: Finasteride Tablets USP
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02355043
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84031
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02355043
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Finasteride · DIN 02389878 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Finasteride · DIN 02389878
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-09-28
Health Canada: Marketed since 2012-07-25 · brand MINT-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87534 · Verify on the e-Formulary ↗ (DIN 02389878)
Source record
DIN 02389878: Mint-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389878
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87534
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02389878
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Finasteride · DIN 02535637 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Finasteride · DIN 02535637
Manufacturer: Nora Pharma; listing date 2026-07-31
Health Canada: Marketed since 2026-04-21 · brand NRA-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Nora pharma inc · schedule Prescription
NRA-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102447 · Verify on the e-Formulary ↗ (DIN 02535637)
Source record
DIN 02535637: NRA-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535637
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102447
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535637
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Novo-Finasteride · DIN 02348500 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Novo-Finasteride · DIN 02348500
Manufacturer: Teva Canada Limited; listing date 2010-06-14
Health Canada: Marketed since 2011-08-12 · brand TEVA-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Teva canada limited · schedule Prescription
Novo-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83386 · Verify on the e-Formulary ↗ (DIN 02348500)
Source record
DIN 02348500: Novo-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348500
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83386
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2026-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02348500
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Finasteride · DIN 02310112 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Finasteride · DIN 02310112
Manufacturer: Pharmascience Inc.; listing date 2010-06-14
Health Canada: Marketed since 2010-03-17 · brand PMS-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Pharmascience inc · schedule Prescription
PMS-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79578 · Verify on the e-Formulary ↗ (DIN 02310112)
Source record
DIN 02310112: PMS-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310112
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79578
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2023-01-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02310112
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Proscar · DIN 02010909 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Proscar (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Proscar · DIN 02010909
Manufacturer: Organon Canada Inc.; listing date 2004-07-20
Health Canada: Marketed since 2022-07-19 · brand PROSCAR · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13370 · Verify on the e-Formulary ↗ (DIN 02010909)
Source record
DIN 02010909: Proscar
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id OCI
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.6891; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02010909
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13370
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2020-11-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02010909
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Finasteride · DIN 02455013 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Finasteride · DIN 02455013
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2024-06-27 · brand RIVA-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94182 · Verify on the e-Formulary ↗ (DIN 02455013)
Source record
DIN 02455013: Riva-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id RIA
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455013
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94182
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: resolved shortage (ended 2024-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02455013
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Finasteride 1mg · DIN 02428148 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Finasteride 1mg · DIN 02428148
Manufacturer: Auro Pharma Inc.; listing date 2015-02-26
Health Canada: Marketed since 2014-11-12 · brand AURO-FINASTERIDE 1MG · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Auro pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91262 · Verify on the e-Formulary ↗ (DIN 02428148)
Source record
DIN 02428148: Auro-Finasteride 1mg
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id AUR
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1455; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428148
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91262
Interchangeable products
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428148
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Finasteride · DIN 02445085 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Finasteride · DIN 02445085
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2015-10-14 · brand FINASTERIDE · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93029 · Verify on the e-Formulary ↗ (DIN 02445085)
Source record
DIN 02445085: Finasteride
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id SAI
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1453; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445085
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93029
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: resolved shortage (ended 2018-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445085
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Finasteride · DIN 02447568 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Finasteride · DIN 02447568
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2015-11-25 · brand FINASTERIDE · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93314 · Verify on the e-Formulary ↗ (DIN 02447568)
Source record
DIN 02447568: Finasteride
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id SIV
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1455; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447568
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93314
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: resolved shortage (ended 2020-11-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447568
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Finasteride Tablets · DIN 02554461 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Finasteride Tablets · DIN 02554461
Manufacturer: Jamp Pharma Corporation; listing date 2025-11-28
Health Canada: Marketed since 2026-03-02 · brand JAMP FINASTERIDE TABLETS · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104332 · Verify on the e-Formulary ↗ (DIN 02554461)
Source record
DIN 02554461: Jamp Finasteride Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id JPC
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1453; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554461
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104332
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554461
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Finasteride · DIN 02537427 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Finasteride · DIN 02537427
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-02-29
Health Canada: Marketed since 2024-05-15 · brand MINT-FINASTERIDE · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Mint pharmaceuticals inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102614 · Verify on the e-Formulary ↗ (DIN 02537427)
Source record
DIN 02537427: Mint-Finasteride
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id MIN
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1453; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537427
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102614
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02537427
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Finasteride · DIN 02320169 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Finasteride · DIN 02320169
Manufacturer: Pharmascience Inc.; listing date 2010-07-20
Health Canada: Marketed since 2010-05-13 · brand PMS-FINASTERIDE · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80561 · Verify on the e-Formulary ↗ (DIN 02320169)
Source record
DIN 02320169: PMS-Finasteride
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id PMS
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1453; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02320169
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80561
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
Propecia · DIN 02238213 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: resolved shortage (ended 2018-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02320169
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Propecia · DIN 02238213 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)Savings card: RxHelp ONE lists Propecia (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Propecia · DIN 02238213
Manufacturer: Organon Canada Inc.; listing date 2010-07-20
Health Canada: Marketed since 2022-05-11 · brand PROPECIA · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Organon canada inc. · schedule Prescription
Propecia: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61606 · Verify on the e-Formulary ↗ (DIN 02238213)
Source record
DIN 02238213: Propecia
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id OCI
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238213
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61606
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Sandoz Finasteride A · DIN 02339471 · not recorded
Shortage status: resolved shortage (ended 2022-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238213
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Finasteride A · DIN 02339471 · 1mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Finasteride A · DIN 02339471
Manufacturer: Sandoz Canada Inc.; listing date 2010-07-20
Health Canada: Marketed since 2010-05-12 · brand SANDOZ FINASTERIDE A · ATC D11AX10 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 1 MG · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82509 · Verify on the e-Formulary ↗ (DIN 02339471)
Source record
DIN 02339471: Sandoz Finasteride A
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000612; group id 914; item number 2187; lccId None; manufacturer id SDZ
Source form: Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.1453; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02339471
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82509
Interchangeable products
Auro-Finasteride 1mg · DIN 02428148 · not recorded
Finasteride · DIN 02445085 · not recorded
Finasteride · DIN 02447568 · not recorded
Jamp Finasteride Tablets · DIN 02554461 · not recorded
Mint-Finasteride · DIN 02537427 · not recorded
PMS-Finasteride · DIN 02320169 · not recorded
Propecia · DIN 02238213 · not recorded
Shortage status: resolved shortage (ended 2024-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02339471
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Finasteride · DIN 02365383 · 5mg · tablet
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Finasteride · DIN 02365383
Manufacturer: Apotex Inc.; listing date 2011-09-15
Health Canada: Dormant since 2024-02-24 · brand APO-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Apotex inc · schedule Prescription
Apo-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85029 · Verify on the e-Formulary ↗ (DIN 02365383)
Source record
DIN 02365383: Apo-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02365383
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85029
Interchangeable products
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: active shortage (reported 2024-02-13, last updated 2024-02-16) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02365383
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-02-24 — choose a marketed DIN from the same-category list.
Jamp-Finasteride · DIN 02357224 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredDormant since 2026-08-03 · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Finasteride · DIN 02357224
Manufacturer: Jamp Pharma Corporation; listing date 2011-03-15
Health Canada: Dormant since 2026-08-03 · brand JAMP-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84235 · Verify on the e-Formulary ↗ (DIN 02357224)
Source record
DIN 02357224: Jamp-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357224
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84235
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: active shortage (reported 2024-08-23, estimated to end 2026-12-31, last updated 2026-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357224
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
M-Finasteride · DIN 02522489 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 requiredDormant since 2026-07-31 · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Finasteride · DIN 02522489
Manufacturer: Mantra Pharma Inc.; listing date 2022-11-30
Health Canada: Dormant since 2026-07-31 · brand M-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Mantra pharma inc · schedule Prescription
M-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101160 · Verify on the e-Formulary ↗ (DIN 02522489)
Source record
DIN 02522489: M-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id MAT
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522489
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101160
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522489
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-31 — choose a marketed DIN from the same-category list.
Ratio-Finasteride · DIN 02306905 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 required; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.Discontinued 2018-06-22 · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Write on scriptLU code 384, 385 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ratio-Finasteride · DIN 02306905
Manufacturer: Ratiopharm Inc.; listing date 2010-06-14
Health Canada: Cancelled post market since 2018-06-22 · brand RATIO-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Teva canada limited · schedule Prescription
Ratio-Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79259 · Verify on the e-Formulary ↗ (DIN 02306905)
Source record
DIN 02306905: Ratio-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id RPH
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02306905
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79259
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02306905
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Sandoz Finasteride · DIN 02322579 · 5mg · tablet
Limited Use — Reason for Use code 384, 385 required; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued 2026-07-31 · checked 2026-09-02
StatusLimited Use — Reason for Use code 384, 385 required; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptLU code 384, 385 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Finasteride · DIN 02322579
Manufacturer: Sandoz Canada Inc.; listing date 2010-04-23
Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Finasteride: Formulary list price $0.3506/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3506 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80802 · Verify on the e-Formulary ↗ (DIN 02322579)
Source record
DIN 02322579: Sandoz Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2188; lccId 00155; manufacturer id SDZ
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322579
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80802
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
Jamp-Finasteride · DIN 02357224 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Shortage status: discontinued (2025-04-01, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322579
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.